AFC-HD AMS Life Science, Sep-Nov (1Q) Ordinary Profit Increases by 5%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Jan 14, 2026 3:30 pm JST Earnings

2927 AFC-HD AMS Life Science Co.,Ltd. 【J-GAAP】

Earnings Report

AFC-HD AMS Life Science Co.,Ltd. <2927> [TSE Std] announced its financial results after the market closed on January 14th (15:30). The consolidated ordinary profit for the first quarter of the fiscal year ending August 2026 (September to November) increased 5.0% from the same period last year, reaching 0.73 billion yen. Progress toward the plan for the six months ending February (first half) of 1.33 billion yen was 55.4%, also surpassing the five-year average of 47.2%.

In the most recent three-month period, from September to November (1Q), the operating profit margin improved from 7.9% in the same period last year to 9.0%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Sep - Nov, 2023	6,786	478	489	318	22.8	46.1	Jan 12, 2024	J-GAAP
Sep - Nov, 2024	8,189	650	704	460	32.7	52.9	Jan 14, 2025	J-GAAP
Sep - Nov, 2025	8,547	771	739	522	36.7	55.4	Jan 14, 2026	J-GAAP
YoY	+4.4%	+18.6%	+5.0%	+13.5%	+12.2%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep - Feb, 2024	16,614	1,294	1,332	881	62.7	16	Apr 14, 2025	J-GAAP
Sep - Feb, 2025 Guidance	16,725	1,297	1,334	883	61.7	18	Oct 15, 2025	J-GAAP
YoY	+0.7%	+0.2%	+0.2%	+0.2%	-1.6%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Aug, 2024	30,185	1,916	1,921	1,252	89.2	30	Oct 15, 2024	J-GAAP
Aug, 2025	32,655	2,409	2,443	1,448	103.0	34	Oct 15, 2025	J-GAAP
Aug, 2026 Guidance	34,137	2,545	2,445	1,462	102.1	36	Oct 15, 2025	J-GAAP
YoY	+4.5%	+5.6%	+0.1%	+1.0%	-0.8%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Sep - Nov, 2024	8,189	650	704	460	32.7	7.9	Jan 14, 2025	J-GAAP
Dec - Feb, 2024	8,425	644	628	421	29.9	7.6	Apr 14, 2025	J-GAAP
Mar - May, 2025	8,123	559	536	531	37.8	6.9	Jul 10, 2025	J-GAAP
Jun - Aug, 2025	7,918	556	575	36	2.6	7.0	Oct 15, 2025	J-GAAP
Sep - Nov, 2025	8,547	771	739	522	36.7	9.0	Jan 14, 2026	J-GAAP
YoY	+4.4%	+18.6%	+5.0%	+13.5%	+12.2%